Molecular basis for the antiandrogen withdrawal syndrome

Hiroshi Miyamoto, Mujib M. Rahman, Chawnshang Chang

Research output: Contribution to journalReview articlepeer-review

Abstract

In patients with prostate cancer who manifest disease progression during combined androgen blockade therapy, discontinuation of antiandrogen treatment might result in prostate-specific antigen decline, often associated with clinical improvement. The response called antiandrogen withdrawal syndrome is thus acknowledged as a general phenomenon. However, molecular mechanisms responsible for this syndrome are not completely understood. This article outlines the proposed mechanisms, including alterations of androgen receptor gene and its coregulatory proteins and activation of the signal transduction pathway, and the potential therapeutic approaches based on the specific mechanisms.

Original languageEnglish (US)
Pages (from-to)3-12
Number of pages10
JournalJournal of cellular biochemistry
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2004

Keywords

  • Androgen receptor
  • Androgen receptor coregulator
  • Combined androgen blockade
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Molecular basis for the antiandrogen withdrawal syndrome'. Together they form a unique fingerprint.

Cite this